Literature DB >> 16139171

Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia.

Daniel J Müller1, Vincenzo De Luca, Tricia Sicard, Nicole King, Rudi Hwang, Jan Volavka, Pal Czobor, Brian B Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P McEvoy, Jeffrey A Lieberman, Herbert Y Meltzer, James L Kennedy.   

Abstract

G-proteins are composed of alpha, beta and gamma subunits. Once activated, these subunits play a major role in the conversion of external receptor activation into intracellular signals. The functional C825T polymorphism of the beta3 subunit gene (GNB3) has recently been shown to modulate antidepressant response, with the T-allele conferring an increased signaling and being associated with favorable antidepressant response. We hypothesized that this polymorphism may be associated with response to antipsychotics in a population of 145 chronic schizophrenic patients deriving from two study-samples and being mainly treated with clozapine for up to 6 months. Overall, the C/C genotype was significantly associated with relative clinical improvement as measured by Brief Psychiatric Rating Scale (BPRS) change scores after 6 and 12 weeks (p<0.01 and p=0.03, respectively), with estimated effect sizes ranging from 4.8 to 7%. Our results further suggest that this effect is only attributable to Caucasians when compared to African-Americans. Moreover, our findings point to the role of intracellular mechanisms in antipsychotic response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139171     DOI: 10.1016/j.euroneuro.2005.02.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  21 in total

1.  Pharmacogenetics of antipsychotic treatment response and side effects.

Authors:  B Mackenzie; Rp Souza; O Likhodi; Ak Tiwari; Cc Zai; J Sturgess; Dj Müller
Journal:  Therapy       Date:  2010-03

2.  Distribution of the GNB3 825C>T polymorphism among Brazilians: impact of population structure.

Authors:  Daniela D Vargens; Lucas Almendra; Cláudio J Struchiner; Guilherme Suarez-Kurtz
Journal:  Eur J Clin Pharmacol       Date:  2007-12-06       Impact factor: 2.953

Review 3.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 4.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 5.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 6.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

7.  Exploring Biologic Predictors Response Disparities to Atypical Antipsychotics among Blacks: A Quasi-Systematic Review.

Authors:  Rebecca N Jerome; Jill M Pulley; Nila A Sathe; Shanthi Krishnaswami; Alyssa B Dickerson; Katherine J Worley; Consuelo H Wilkins
Journal:  Ethn Dis       Date:  2020-04-02       Impact factor: 1.847

8.  The pharmacogenetics of symptom response to antipsychotic drugs.

Authors:  Gavin P Reynolds
Journal:  Psychiatry Investig       Date:  2012-01-09       Impact factor: 2.505

Review 9.  [Genetics of weight gain associated with antipsychotic medications].

Authors:  D J Müller; C Peter; I Puls; E J Brandl; U E Lang; J Gallinat; A Heinz
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

10.  Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.

Authors:  Olalla Robles; Arantzazu Zabala; Igor Bombín; Mara Parellada; Dolores Moreno; Ana Ruiz-Sancho; Celso Arango
Journal:  Schizophr Bull       Date:  2009-08-25       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.